Country-based report: The safety of omalizumab treatment in pregnant patients with asthma

Simple item page
dc.contributor.authorGemicioğlu B.
dc.contributor.authorYalçin A.D.
dc.contributor.authorHavlucu Y.
dc.contributor.authorKarakaya G.
dc.contributor.authorÖzdemir L.
dc.contributor.authorKeren M.
dc.contributor.authorBavbek S.
dc.contributor.authorEdiger D.
dc.contributor.authorOğuzülgen İ.K.
dc.contributor.authorÖzşeker Z.F.
dc.contributor.authorYorgancioğlu A.
dc.date.accessioned2024-07-22T08:06:27Z
dc.date.available2024-07-22T08:06:27Z
dc.date.issued2021
dc.description.abstractBackground/aim: We aimed to report outcomes of pregnant patients with asthma under omalizumab treatment and their infants in our country. Materials and methods: Patients with asthma who received omalizumab for at least 6 months and at least one dose during their pregnancy were retrospectively evaluated using a questionnaire regarding their disease and therapy and the health of their infants. Results: Twenty pregnant patients and their 23 infant’s data were analyzed. The mean delivery age was 31.8 ± 7.4 years. They received omalizumab for 28.9 ± 21.8 months. Eight (36.4%) patients showed exacerbation of the disease during pregnancy. Forced expiratory volume in 1 s (FEV1) and asthma control test (ACT) scores at the starting time of omalizumab administration, first month of the pregnancy, and after delivery were 71 ± 18%, 83.4 ± 10.5%, and 80.5 ± 13% (FEV1), and 11.9 ± 4.9, 20.2 ± 2.6, and 20.4 ± 2.2 (ACT), respectively. One patient gave birth to twin infants, two patients to two infants each in different years, and 17 to one infant each. Three (13%) infants had low birth weight and five (21.7%) were born prematurely. No congenital anomalies were detected. Seven (30.4%) infants presented atopic diseases during their life. Conclusion: Omalizumab treatment during pregnancy seems to be safe for both patients and their infants. © TÜBİTAK.
dc.identifier.DOI-ID10.3906/SAG-2101-341
dc.identifier.issn13000144
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13542
dc.language.isoEnglish
dc.publisherTurkiye Klinikleri
dc.rightsAll Open Access; Bronze Open Access; Green Open Access
dc.subjectAdult
dc.subjectAnti-Asthmatic Agents
dc.subjectAntibodies, Monoclonal, Humanized
dc.subjectAsthma
dc.subjectFemale
dc.subjectForced Expiratory Volume
dc.subjectHumans
dc.subjectOmalizumab
dc.subjectPregnancy
dc.subjectPregnancy Complications
dc.subjectRetrospective Studies
dc.subjectTreatment Outcome
dc.subjectbeta adrenergic receptor stimulating agent
dc.subjectcorticosteroid
dc.subjecthistamine agonist
dc.subjectimmunoglobulin E
dc.subjectleukotriene receptor blocking agent
dc.subjectlong acting drug
dc.subjectomalizumab
dc.subjectantiasthmatic agent
dc.subjectmonoclonal antibody
dc.subjectomalizumab
dc.subjectadult
dc.subjectallergic rhinitis
dc.subjectallergy
dc.subjectApgar score
dc.subjectArticle
dc.subjectasthma
dc.subjectAsthma Control Test
dc.subjectatopy
dc.subjectbirth weight
dc.subjectblood cell count
dc.subjectbody mass
dc.subjectcase study
dc.subjectcesarean section
dc.subjectclinical article
dc.subjectcomorbidity
dc.subjectcontrolled study
dc.subjectdemography
dc.subjectdisease exacerbation
dc.subjectdrug safety
dc.subjectdrug therapy
dc.subjecteducation
dc.subjectemployment
dc.subjecteosinophil count
dc.subjectfemale
dc.subjectfirst trimester pregnancy
dc.subjectforced expiratory volume
dc.subjectforced vital capacity
dc.subjectgestational age
dc.subjecthematocrit
dc.subjecthousewife
dc.subjecthuman
dc.subjectimmunoglobulin blood level
dc.subjectinfant
dc.subjectlow birth weight
dc.subjectobstetric delivery
dc.subjectoccupation
dc.subjectoutcome assessment
dc.subjectpatient compliance
dc.subjectpharmacokinetics
dc.subjectplatelet count
dc.subjectpregnancy
dc.subjectprematurity
dc.subjectprick test
dc.subjectquestionnaire
dc.subjectretrospective study
dc.subjectsecond trimester pregnancy
dc.subjectsmoking
dc.subjectspirometry
dc.subjectstructured questionnaire
dc.subjectthird trimester pregnancy
dc.subjectasthma
dc.subjectpregnancy
dc.subjectpregnancy complication
dc.subjecttreatment outcome
dc.titleCountry-based report: The safety of omalizumab treatment in pregnant patients with asthma
dc.typeArticle

Files

Collections

Scopus Koleksiyonu